Hematologic Oncology Update, Issue 3, 2016 (Video Program) - Video 14


Activity and tolerability of the Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib (ACP-196) in CLL
2:26 minutes.

Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Acute and chronic leukemias and myeloproliferative neoplasms

Multiple myeloma (MM)